Dominic Plucinski, MD
Cardiovascular Disease · Edina, MNNPI 1902856974
Payments from drug & device makers
Across 23 payments — averaging $1484.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$34K
- Medtronic$332
- Amgen$62
- E.r. Squibb & Sons, L.L.C.$47
- Esperion Therapeutics, Inc.$46
- Biocompatibles, Inc.$17
- plus $31 from 2 others
What the payments were for
- Food & beverage$5342%
- Education$14,40042%
- Other$19,20056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 7 | $33,600 |
| Medtronic(2 entities) | 4 | $332 |
| Amgen | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Esperion Therapeutics, Inc. | 2 | $46 |
| Biocompatibles, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Itamar Medical Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$24,000
- EVLT$9,600
- VenaSeal$241
How this compares
$34,134 in reported general payments places this provider in the 70th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $38,591 |
| Repatha SureclickEvolocumab | 21 | $16,501 |
| Ezetimibe | 64 | $1,699 |
| Metoprolol Succinate | 77 | $1,258 |
| Pravastatin Sodium | 33 | $592 |
| Rosuvastatin Calcium | 34 | $495 |
| Losartan Potassium | 34 | $366 |
| Olmesartan Medoxomil | 24 | $311 |
| Spironolactone | 25 | $277 |
| Atorvastatin Calcium | 28 | $246 |
| Carvedilol | 20 | $217 |
| Chlorthalidone | 15 | $195 |
| Amlodipine Besylate | 13 | $74 |
| Lisinopril | 17 | $72 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Edina
- David LinEdina$256K
- Jae OhRochester$7.9M
- Yogesh ReddyRochester$7.9M
- Mayra GuerreroRochester$7.1M
- Martha GroganRochester$6.3M
- Leslie ForgoshSaint Paul$6.2M
- Jeffrey ChambersMinneapolis$3.6M
- Mackram EleidRochester$3.5M
- David HolmesRochester$2.4M
- Mohamad Adnan AlkhouliRochester$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.